Drugs / BIIB061
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02521545 | Jul → Aug 2015 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02228707 | Aug 2014 → May 2016 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02071121 | Dec 2013 → Sep 2014 | — | Biogen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04079088 | Jun 2021 → Sep 2024 | multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02071121 ↗ |
| Route | Oral | “BIIB061 capsules for oral administration” NCT02071121 ↗ |